Bridging the Data Integrity Gap in Pharmaceutical Quality Control: Ensuring Reliability for Advanced Medicinal Products

August 30, 2026

European Pharmaceutical Review EU

Overview

The critical importance of closing the data integrity gap in pharmaceutical quality control has been re-emphasized. For advanced medicinal products like cell and gene therapies, stringent reliability and accuracy in data collection, management, and analysis are essential due to complex processes and high patient safety demands. The article urges comprehensive data integrity strategies to meet regulatory expectations and ensure product quality and patient safety.

In Depth

Key Findings

In the domain of pharmaceutical quality control, the imperative to decisively bridge data integrity gaps has once again been brought to the forefront. This article underscores that data integrity is a pivotal element directly linked to product reliability and patient safety, particularly in the manufacturing and quality assurance of advanced medicinal products, including cell and gene therapies.

Technical / Clinical Details

Data integrity refers to the accuracy, completeness, consistency, and reliability of data, necessitating adherence to principles such as ALCOA (Attributable, Legible, Contemporaneous, Original, Accurate). The manufacturing processes for advanced medicinal products, such as iPSC-derived products and gene therapies, are inherently complex and multi-staged, often involving significant manual intervention and requiring real-time monitoring. In such environments, inadequate data recording, untraceable data alterations, data inconsistencies between systems, and cybersecurity risks can all create data integrity gaps. The article highlights that digital solutions like electronic document management systems (EDMS), audit trail functionalities, automated data collection, and even blockchain technology are essential to address these challenges and ensure data trustworthiness across its entire lifecycle. Specifically, the implementation of validated software and robust IT infrastructure is highly recommended.

Background & Context

Global regulatory authorities (e.g., FDA, EMA, PMDA) have progressively imposed stricter requirements for data integrity in pharmaceutical manufacturing. This stems from past experiences of product recalls and approval delays caused by data manipulation or inadequate record-keeping. Cell and gene therapy products, due to their personalized nature, complex manufacturing, high costs, and direct life-saving impact on patients, demand particularly high levels of quality and reliability. A lack of data integrity can lead to product quality failures, supply interruptions, and even adverse patient outcomes, severely impacting not only corporate reputation but also public health. Therefore, ensuring data integrity is not merely a matter of regulatory compliance but an ethical responsibility for companies.

Strategic Significance & Outlook

The pharmaceutical industry must foster a pervasive culture of data integrity throughout organizations, strengthening approaches on both technological solutions and human factors. This includes continuous employee training, strict adherence to Standard Operating Procedures (SOPs), and investment in cutting-edge digital technologies. Enhanced data integrity will enable the rapid and safe development and supply of advanced medicinal products, ultimately contributing to broader patient access to innovative therapies. Continuous improvement and technological innovation in this area are indispensable for shaping the future of pharmaceutical manufacturing and will form the bedrock for sustainable growth across the entire industry.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.